This title appears in the Scientific Report :
2020
Please use the identifier:
http://hdl.handle.net/2128/24866 in citations.
Please use the identifier: http://dx.doi.org/10.2967/jnumed.119.229542 in citations.
An 18 F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18 F-JK-PSMA-7 During the First Year of Application
An 18 F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18 F-JK-PSMA-7 During the First Year of Application
In preclinical trials, the recently developed tracer 2-methoxy-18F-DCFPyL (18F-JK-prostate-specific membrane antigen [PSMA]-7) has shown favorable properties regarding clinical performance and radiochemical accessibility. The aim of this study was to evaluate the clinical utility of 18F-JK-PSMA-7 fo...
Saved in:
Personal Name(s): | Dietlein, Felix |
---|---|
Hohberg, Melanie / Kobe, Carsten / Zlatopolskiy, Boris D. / Krapf, Philipp / Endepols, Heike / Täger, Philipp / Hammes, Jochen / Heidenreich, Axel / Neumaier, Bernd / Drzezga, Alexander / Dietlein, Markus (Corresponding author) | |
Contributing Institute: |
Molekulare Organisation des Gehirns; INM-2 Nuklearchemie; INM-5 |
Published in: | Journal of nuclear medicine, 61 (2020) 2, S. 202 - 209 |
Imprint: |
New York, NY
Soc.
2020
|
PubMed ID: |
31324713 |
DOI: |
10.2967/jnumed.119.229542 |
Document Type: |
Journal Article |
Research Program: |
Neuroimaging |
Link: |
Get full text OpenAccess OpenAccess Get full text |
Publikationsportal JuSER |
Please use the identifier: http://dx.doi.org/10.2967/jnumed.119.229542 in citations.
In preclinical trials, the recently developed tracer 2-methoxy-18F-DCFPyL (18F-JK-prostate-specific membrane antigen [PSMA]-7) has shown favorable properties regarding clinical performance and radiochemical accessibility. The aim of this study was to evaluate the clinical utility of 18F-JK-PSMA-7 for PET/CT imaging of patients with prostate cancer. Methods: In an Institutional Review Board–approved pilot study, the initial clinical utility of PET/CT imaging with 18F-JK-PSMA-7 was directly compared with 68Ga-PSMA-11 PET/CT in a group of 10 patients with prostate cancer. The 2 PSMA tracers were administered to each patient less than 3 wk apart. Next, we analyzed the data of 75 consecutive patients who had undergone clinical 18F-JK-PSMA-7 PET/CT imaging for tumor localization of biochemical recurrence (BCR). Results: The pilot study in 10 patients who were examined with both PSMA tracers demonstrated that 18F-JK-PSMA-7 was at least equivalent to 68Ga-PSMA-11. All unequivocally 68Ga-PSMA-11–positive lesions could be also detected using 18F-JK-PSMA-7, and in 4 patients additional suspected PSMA-positive lesions were identified (1 patient changed from PSMA-negative to PSMA-positive). In patients with BCR (after prostatectomy or radiotherapy), the capacity of 18F-JK-PSMA-7 PET/CT to detect at least one PSMA-positive lesion was 84.8%. The prostate-specific antigen (PSA)–stratified detection rate of 18F-JK-PSMA-7 after prostatectomy varied among 54.5% (6/11 patients; PSA < 0.5 μg/L), 87.5% (14/16 patients; PSA 0.5–2 μg/L), and 90.9% (20/22 patients; PSA > 2 μg/L). Conclusion: The tracer 18F-JK-PSMA-7 was found to be safe and clinically useful. We demonstrated that 18F-JK-PSMA-7 was not inferior when directly compared with 68Ga-PSMA-11 in a pilot study but indeed identified additional PSMA-avid suspected lesions in oligometastasized patients with BCR. In a subsequent analysis of a clinical cohort of BCR patients, 18F-JK-PSMA-7 was useful in tumor localization. 18F-JK-PSMA-7 is recommended for future prospective trials. |